{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:26:32Z","timestamp":1788387992560,"version":"build-2803163510"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Monoclonal antibody therapy is a new treatment strategy for many types of diseases including cancers and autoimmune diseases, realizing a high efficacy and tolerability. In multiple sclerosis (MS) and neuromyelitis optica (NMO) spectrum disorders, several monoclonal antibodies have been suggested to decrease the incidence of clinical relapse and the disease activity. In MS, anti-\u03b14 integrin (natalizumab), anti-CD52 (alemtuzumab), anti-CD25 (daclizumab) and anti-CD20 (ocrelizumab) have been shown to effectively reduce the relapses in randomized controlled trials and have been approved by the Food and Drug Administration. Specifically, ocrelizumab is the first drug that has shown significant suppression of brain volume loss and suppression of chronic disability progression. In NMO, though there have yet to be any approved monoclonal antibodies, rituximab, anti-complement C5 (eculizumab), anti-IL-6 receptor (tocilizumab), anti-CD19 (inebilizumab) and non-pathogenic anti-aquaporin 4 (aquaporumab) have been suggested to be effective, and some of these are now under clinical trials. Aquaporumab is a non-pathogenic recombinant human monoclonal antibody that competitively inhibits the binding of the pathogenic auto-antibody against aquaporin 4 in NMO patients; thus, it is expected to be highly disease specific with less non-specific adverse events. Some of these monoclonal antibodies in MS and NMO are known to cause several notable adverse events. Natalizumab and rituximab increase the risk of progressive multifocal leukoencephalopathy. Eculizumab increases the risk of meningococcal infection. Tocilizumab is known to cause intestinal diverticulitis that can cause intestinal perforation. In this review, we summarize the characteristics of, evidence for and notable adverse events of each monoclonal antibody in MS and NMO.<\/jats:p>","DOI":"10.1093\/intimm\/dxx037","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T19:15:26Z","timestamp":1499109326000},"page":"327-335","source":"Crossref","is-referenced-by-count":25,"title":["Efficiency of antibody therapy in demyelinating diseases"],"prefix":"10.1093","volume":"29","author":[{"given":"Tetsuya","family":"Akaishi","sequence":"first","affiliation":[{"name":"Department of Neurology, Tohoku University School of Medicine 1 , Seiryo-machi 1-1, Aoba-ku, Sendai 980-8574 , Japan"},{"name":"Department of Neurology, Yonezawa National Hospital 2 , Misawa 26100-1, Yonezawa 992-1202 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-8948","authenticated-orcid":false,"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University School of Medicine 1 , Seiryo-machi 1-1, Aoba-ku, Sendai 980-8574 , Japan"},{"name":"Department of Neurology, Tohoku Medical and Pharmaceutical University 3 , Fukumuro 1-12-1, Miyagino-ku, Sendai 983-8512 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"key":"2022093019084548000_CIT0001","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol"},{"key":"2022093019084548000_CIT0002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol"},{"key":"2022093019084548000_CIT0003","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med"},{"key":"2022093019084548000_CIT0004","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneur.65.7.913","article-title":"Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis","volume":"65","author":"Waters","year":"2008","journal-title":"Arch. Neurol"},{"key":"2022093019084548000_CIT0005","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/WNO.0b013e318254c62d","article-title":"Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis","volume":"32","author":"Khanna","year":"2012","journal-title":"J. Neuroophthalmol"},{"key":"2022093019084548000_CIT0006","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jneuroim.2016.09.007","article-title":"Different etiologies and prognoses of optic neuritis in demyelinating diseases","volume":"299","author":"Akaishi","year":"2016","journal-title":"J. Neuroimmunol"},{"key":"2022093019084548000_CIT0007","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jneuroim.2016.02.004","article-title":"Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica","volume":"293","author":"Akaishi","year":"2016","journal-title":"J. Neuroimmunol"},{"key":"2022093019084548000_CIT0008","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat. Rev. Neurol"},{"key":"2022093019084548000_CIT0009","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/intimm\/dxh056","article-title":"Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association","volume":"16","author":"Mantegazza","year":"2004","journal-title":"Int. Immunol"},{"key":"2022093019084548000_CIT0010","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/archneurol.2011.2956","article-title":"Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis","volume":"69","author":"Rostasy","year":"2012","journal-title":"Arch. Neurol"},{"key":"2022093019084548000_CIT0011","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","article-title":"MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study","volume":"87","author":"Akaishi","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2022093019084548000_CIT0012","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"2022093019084548000_CIT0013","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"2022093019084548000_CIT0014","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"2022093019084548000_CIT0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e318207b1f6","article-title":"Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"76","author":"Cortese","year":"2011","journal-title":"Neurology"},{"key":"2022093019084548000_CIT0016","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1590\/S0004-282X2012000100012","article-title":"Treatment of neuromyelitis optica: an evidence based review","volume":"70","author":"Sato","year":"2012","journal-title":"Arq. Neuropsiquiatr"},{"key":"2022093019084548000_CIT0017","doi-asserted-by":"crossref","first-page":"545","DOI":"10.12998\/wjcc.v3.i7.545","article-title":"Treatment strategies for multiple sclerosis: when to start, when to change, when to stop?","volume":"3","author":"Gajofatto","year":"2015","journal-title":"World J. Clin. Cases"},{"key":"2022093019084548000_CIT0018","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord"},{"key":"2022093019084548000_CIT0019","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult. Scler. Relat. Disord"},{"key":"2022093019084548000_CIT0020","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI12440","article-title":"Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels","volume":"108","author":"Vajkoczy","year":"2001","journal-title":"J. Clin. Invest"},{"key":"2022093019084548000_CIT0021","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.immuni.2009.09.012","article-title":"The gut immune barrier and the blood\u2013brain barrier: are they so different?","volume":"31","author":"Daneman","year":"2009","journal-title":"Immunity"},{"key":"2022093019084548000_CIT0022","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"2022093019084548000_CIT0023","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N. Engl. J. Med"},{"key":"2022093019084548000_CIT0024","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"2022093019084548000_CIT0025","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/ene.12992","article-title":"Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years","volume":"23","author":"Zivadinov","year":"2016","journal-title":"Eur. J. Neurol"},{"key":"2022093019084548000_CIT0026","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1128\/jcm.34.12.2929-2932.1996","article-title":"Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy","volume":"34","author":"Hammarin","year":"1996","journal-title":"J. Clin. Microbiol"},{"key":"2022093019084548000_CIT0027","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2022093019084548000_CIT0028","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/1756285608101861","article-title":"Natalizumab in the treatment of multiple sclerosis","volume":"2","author":"Yaldizli","year":"2009","journal-title":"Ther. Adv. Neurol. Disord"},{"key":"2022093019084548000_CIT0029","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J. Neurol"},{"key":"2022093019084548000_CIT0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/ane.12250","article-title":"What to expect after natalizumab cessation in a real-life setting","volume":"130","author":"Salhofer-Polanyi","year":"2014","journal-title":"Acta Neurol. Scand"},{"key":"2022093019084548000_CIT0031","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch. Neurol"},{"key":"2022093019084548000_CIT0032","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1385\/1-59259-076-4:243","article-title":"From laboratory to clinic: the story of CAM PA TH-1","volume":"40","author":"Hale","year":"2000","journal-title":"Methods Mol. Med"},{"key":"2022093019084548000_CIT0033","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","article-title":"The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy","volume":"253","author":"Coles","year":"2006","journal-title":"J. Neurol"},{"key":"2022093019084548000_CIT0034","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00415-008-0696-y","article-title":"Campath 1-H treatment in patients with aggressive relapsing\u2013remitting multiple sclerosis","volume":"255","author":"Hirst","year":"2008","journal-title":"J. Neurol"},{"key":"2022093019084548000_CIT0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1468-1331.2011.03507.x","article-title":"A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis","volume":"19","author":"Fox","year":"2012","journal-title":"Eur. J. Neurol"},{"key":"2022093019084548000_CIT0036","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"2022093019084548000_CIT0037","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"2022093019084548000_CIT0038","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"2022093019084548000_CIT0039","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","article-title":"Alemtuzumab more effective than interferon \u03b2-1a at 5-year follow-up of CAMMS223 clinical trial","volume":"78","author":"Coles","year":"2012","journal-title":"Neurology"},{"key":"2022093019084548000_CIT0040","doi-asserted-by":"crossref","first-page":"821","DOI":"10.4158\/EP13020.RA","article-title":"Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review","volume":"19","author":"Aranha","year":"2013","journal-title":"Endocr. Pract"},{"key":"2022093019084548000_CIT0041","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1084\/jem.20051511","article-title":"CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner","volume":"202","author":"Ghiringhelli","year":"2005","journal-title":"J. Exp. Med"},{"key":"2022093019084548000_CIT0042","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1212\/WNL.0b013e318239f7ef","article-title":"Intrathecal effects of daclizumab treatment of multiple sclerosis","volume":"77","author":"Bielekova","year":"2011","journal-title":"Neurology"},{"key":"2022093019084548000_CIT0043","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","article-title":"Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial","volume":"381","author":"Gold","year":"2013","journal-title":"Lancet"},{"key":"2022093019084548000_CIT0044","article-title":"No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study","author":"Kappos","year":"2016","journal-title":"Mult. Scler"},{"key":"2022093019084548000_CIT0045","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","article-title":"Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis","volume":"373","author":"Kappos","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"2022093019084548000_CIT0046","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1592\/phco.29.2.227","article-title":"Daclizumab treatment for multiple sclerosis","volume":"29","author":"Kim","year":"2009","journal-title":"Pharmacotherapy"},{"key":"2022093019084548000_CIT0047","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1756285609356135","article-title":"Practical considerations on the use of rituximab in autoimmune neurological disorders","volume":"3","author":"Kosmidis","year":"2010","journal-title":"Ther. Adv. Neurol. Disord"},{"key":"2022093019084548000_CIT0048","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archneurol.2008.551","article-title":"Long-term B-lymphocyte depletion with rituximab in patients with relapsing\u2013remitting multiple sclerosis","volume":"66","author":"St\u00fcve","year":"2009","journal-title":"Arch. Neurol"},{"key":"2022093019084548000_CIT0049","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"2022093019084548000_CIT0050","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol"},{"key":"2022093019084548000_CIT0051","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann. Neurol"},{"key":"2022093019084548000_CIT0052","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","article-title":"Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis","volume":"68","author":"Clifford","year":"2011","journal-title":"Arch. Neurol"},{"key":"2022093019084548000_CIT0053","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.4254\/wjh.v7.i21.2344","article-title":"Hepatitis B virus reactivation with a rituximab-containing regimen","volume":"7","author":"Tsutsumi","year":"2015","journal-title":"World J. Hepatol"},{"key":"2022093019084548000_CIT0054","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"2022093019084548000_CIT0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"2022093019084548000_CIT0056","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3899\/jrheum.121118","article-title":"Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I\/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics","volume":"40","author":"Kurrasch","year":"2013","journal-title":"J. Rheumatol"},{"key":"2022093019084548000_CIT0057","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch. Neurol"},{"key":"2022093019084548000_CIT0058","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"2022093019084548000_CIT0059","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1634\/theoncologist.2008-0086","article-title":"FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"13","author":"Dmytrijuk","year":"2008","journal-title":"Oncologist"},{"key":"2022093019084548000_CIT0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1096\/fj.99-1003rev","article-title":"The soluble interleukin 6 receptor: mechanisms of production and implications in disease","volume":"15","author":"Jones","year":"2001","journal-title":"FASEB J"},{"key":"2022093019084548000_CIT0061","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.1078231","article-title":"Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells","volume":"299","author":"Pasare","year":"2003","journal-title":"Science"},{"key":"2022093019084548000_CIT0062","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur. J. Immunol"},{"key":"2022093019084548000_CIT0063","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/mi.2008.51","article-title":"Regulatory T cells and the induction of IL-17","volume":"1","author":"Kitani","year":"2008","journal-title":"Mucosal Immunol"},{"key":"2022093019084548000_CIT0064","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2015-207281","article-title":"Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann. Rheum. Dis"},{"key":"2022093019084548000_CIT0065","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"2022093019084548000_CIT0066","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"key":"2022093019084548000_CIT0067","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","article-title":"Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses","volume":"70","author":"Kieseier","year":"2013","journal-title":"JAMA Neurol"},{"key":"2022093019084548000_CIT0068","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202939","article-title":"Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab","author":"Lauenstein","year":"2014","journal-title":"BMJ Case Rep"},{"key":"2022093019084548000_CIT0069","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12883-014-0247-3","article-title":"Interferon-\u03b2-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab","volume":"14","author":"Harmel","year":"2014","journal-title":"BMC Neurol"},{"key":"2022093019084548000_CIT0070","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"2022093019084548000_CIT0071","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/1352458515623862","article-title":"MS arising during Tocilizumab therapy for rheumatoid arthritis","volume":"22","author":"Beauchemin","year":"2016","journal-title":"Mult. Scler"},{"key":"2022093019084548000_CIT0072","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s10067-011-1827-x","article-title":"Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review","volume":"30","author":"Gout","year":"2011","journal-title":"Clin. Rheumatol"},{"key":"2022093019084548000_CIT0073","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1055\/s-0030-1255931","article-title":"Multiple ulcers in the small and large intestines occurred during tocilizumab therapy for rheumatoid arthritis","volume":"43","author":"Iwasa","year":"2011","journal-title":"Endoscopy"},{"key":"2022093019084548000_CIT0074","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","article-title":"Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann. Rheum. Dis"},{"key":"2022093019084548000_CIT0075","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","article-title":"Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthritis Res. Ther"},{"key":"2022093019084548000_CIT0076","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11940-015-0378-x","article-title":"Acute and chronic management of neuromyelitis optica spectrum disorder","volume":"17","author":"Sherman","year":"2015","journal-title":"Curr. Treat. Options Neurol"},{"key":"2022093019084548000_CIT0077","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann. Neurol"},{"key":"2022093019084548000_CIT0078","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0897.1994.tb00873.x","article-title":"Maternal-fetal transport of immunoglobulin G and its subclasses during the third trimester of human pregnancy","volume":"32","author":"Malek","year":"1994","journal-title":"Am. J. Reprod. Immunol"},{"key":"2022093019084548000_CIT0079","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1016\/S0264-410X(03)00334-7","article-title":"Placental transport of immunoglobulin G","volume":"21","author":"Simister","year":"2003","journal-title":"Vaccine"},{"key":"2022093019084548000_CIT0080","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.4049\/jimmunol.1301483","article-title":"Neuromyelitis optica IgG causes placental inflammation and fetal death","volume":"191","author":"Saadoun","year":"2013","journal-title":"J. Immunol"}],"container-title":["International Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/intimm\/article-pdf\/29\/7\/327\/46223863\/intimm_29_7_327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/intimm\/article-pdf\/29\/7\/327\/46223863\/intimm_29_7_327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T20:04:52Z","timestamp":1664568292000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/intimm\/article\/29\/7\/327\/3925945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":80,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,5]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/intimm\/dxx037","relation":{},"ISSN":["0953-8178","1460-2377"],"issn-type":[{"value":"0953-8178","type":"print"},{"value":"1460-2377","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7]]},"published":{"date-parts":[[2017,7,1]]}}}